药品知识产权证券化资产池构建的理论探析

Construction of the asset pool of pharmaceutical intellectual property securitization

我国现有药品知识产权快速流失的主要原因在于庞大后续研发资金缺失,而新药专利资金匮乏的原因,在于新药研发风险高,研发周期长,国内融资渠道单一。药品知识产权证券化正是解决这两种困难的方法。将药品知识产权作为一种资产融入庞大的资本市场,同时满足研发者和投资者的迫切需求。本文将从药品知识产权证券化资产池构建方面来介绍和探讨这一有效的融资途径。

The main reason for the rapid loss of pharmaceutical intellectual property rights of Chinese traditional medicine is the serious lack of follow-up R＆amp;D funds.The cause of the lack of the funds are the high risk of new drug research,the length of R＆amp;D cycle and the domestic single and narrow finacial channel.All of those restrain the development of our pharmaceutical industry.Now,pharmaceutical intellectual property securitization will resolve the problem.It brings pharmaceutical intellectual property right into capital markets as a kind of assets, so it not only meet the urgent need from researchers but also meet the demands from investors. This article will introduce and explore the construction of the asset pool of pharmaceutical intellectual property securitization.